

Cognitive-Behavioral and Pharmacological Treatments for Insomnia: A Combined Approach

Alessandro Cicolin¹, Alessandra Giordano¹

Abstract

Insomnia is the most prevalent sleep disorder (10–40%). It is defined as the subjective perception of difficulty with sleep initiation, duration, consolidation, or quality that occurs despite adequate opportunity for sleep and that results in some form of daytime impairment. Among the typical symptoms, there are fatigue, decreased mood or irritability, general malaise, and cognitive impairment. According to the International Classification of Sleep Disorders 3rd edition, ICSD-3, it has been defined as chronic (lasting more than three months) or short-term insomnia (less than three months).

In clinical practice, the usual therapeutic approach is pharmacological (benzodiazepines, z drugs, slow wave sleep enhancers), even if the American Academy of Sleep Medicine (AASM), the American College of Physicians (ACP), and the European Sleep Research Society (ESRS) guidelines suggest that the first clinical choice should be non-pharmacological (cognitive behavioral therapy). A combined (non-pharmacological and pharmacological) approach could be considered in poor responders to manage drug dependence and to increase compliance to treatment and patients' quality of life.

Keywords: Sleep; Insomnia; Pharmacological Treatment; Non-pharmacological treatment; Cognitive-behavioral therapy for insomnia (CBT-I)

CMI 2020; 14(1): 27–38

<http://dx.doi.org/10.7175/cmi.v14i1.1474>

¹ Sleep Medicine Center, Department of Neuroscience, University of Torino, Torino, Italy

INTRODUCTION

The sleep is one of the most complex and dynamic cerebral phenomena, resulting from the combination or alternation of multiple neurophysiological and neuro-biochemical active processes. Thanks to the application of recent discoveries and techniques and the development of sleep medicine, during the last decade, much knowledge has been acquired about the inner mechanisms that promote, induce, maintain, and interrupt the sleep itself, how its processes take place, and how anatomical sites and their neuronal systems work.

Different modes of sleep exist, based on the presence or absence of rapid eye movements, respectively, rapid eye movements—REM sleep, and non-rapid eye

movements—NREM sleep. The NREM sleep is divided into three stages: N1, N2, and N3 (N3 also defined as “slow waves sleep”, SWS).

To date, four main systems interacting to regulate sleep are known.

1. The circadian oscillator is responsible for the organization of the 24-hour sleep-wake cycle and is located in the supra-chiasmatic nucleus at the hypothalamic level [1].
2. The ultradian oscillator, in the brainstem (REM-off and REM-on neuronal cells), is responsible for the precise alternation NREM and REM sleep [2].
3. The sleep homeostasis controls the propensity to fall asleep and is regulated by the concentration of adenosine in the

Corresponding author
 Prof. Alessandro Cicolin
 Sleep Medicine Center
 Department of Neuroscience
 University of Torino
 Via Cherasco 15
 10126 Torino
 Italy
alessandro.cicolin@unito.it
 tel. +39 011 6335038
 fax. +39 011 6334193

Received: 13 April 2020
 Accepted: 8 July 2020
 Published: 30 July 2020

frontobasal cortex; its quantity is directly proportional to the number of hours we are awake [3].

4. The arousal system regulates the stability of sleep (sleep and awakening). It is controlled by the ascending reticular activating system in the brainstem and by the orexinergic neurons in the lateral hypothalamus [4,5].

INSOMNIA

Definition, Epidemiology, and Symptoms

Insomnia is the most common of all sleep disorders, affecting more than 40% of the population every year, with a much higher prevalence in older age groups and women. Despite that, only 10% of affected subjects have a daytime functioning impairment and need treatment. Insomnia is defined as the subject's perception of inadequate or insufficient sleep and poorly restorative sleep due to reduced quality, duration, or efficiency of sleep itself. It is characterized by difficulty in starting or maintaining sleep or early morning awakening. Insufficient sleep must be associated with daytime symptoms such as fatigue, decreased mood or irritability, memory, and attention impairment. These symptoms can lead to a reduced quality of life and can induce physical disturbances, economic repercussions due to poor performance at work, and sometimes medical and legal problems [6]. Insomnia can, therefore, be defined as a 24-hour sleep disorder. Insomnia is defined as a subjective complaint and doesn't usually require instrumental verification. Diagnosis relies on an accurate interview that should assess bedtime habits, daily symptoms, excessive daytime sleepiness (EDS), awakenings (during night and early morning), regularity and duration of sleep, and the presence of leg movements or snoring during sleep [7]. Taking a complete sleep history will help in determining a differential diagnosis among possible sleep-waking rhythm disorders, sleep-related movement or breathing disorders such as circadian rhythm sleep-wake disorders (CRSWD), restless legs syndrome (RLS), periodic limb movement disorders (PLMD), and obstructive sleep apnea syndrome (OSAS). Difficulty initiating sleep, for example, is a common feature in both insomnia and delayed sleep-wake phase disorder (DSWPD). However, patients affected by DSWPD usually sleep a regular or even more consider-

able amount of time if they can maintain late-rising time. This disorder is also more common in the teenagers. Excessive daytime sleepiness (that is a significant complaint in many cases), lack of attention and concentration, irritability, and behavioral problems are shared with other sleep disorders such as RLS, PLMD, and OSAS, due to sleep fragmentation caused by apneas or leg movements. The repeated episodes of obstruction of the upper airways during sleep in OSAS patients, causing oxyhemoglobin desaturation and micro-arousals, are responsible for memory and attention impairment [8,9], a feature shared with chronic insomnia. Performing actigraphy to determine the sleep-wake rhythm and polysomnography (PSG) or out-of-center sleep testing (OCST) to assess obstructive respiratory events and leg movements would definitely help in diagnosis. Chronic auto-induced sleep restriction should also be considered.

The International Classification of Sleep Disorders (ICSD) 3rd edition (ICSD-3) [6] includes three diagnostic categories for insomnia:

1. chronic insomnia disorder;
2. short-term insomnia disorder; and
3. other insomnia disorder.

Chronic insomnia disorder should be present at least three times per week for at least three months. Short-term insomnia doesn't meet the duration criteria (<3 months).

For many years, insomnia has been classified from an etiopathogenetic point of view that distinguishes primary and secondary forms [10,11].

Primary insomnias are considered to be a distinct diagnostic entity from insomnia, that is a symptom of an underlying medical and psychiatric condition. These patients show a sort of "weakness" of the biological system that regulates sleep, even if sometimes it is possible to find a trigger. They usually begin in young-adult age and, if not treated, may have a chronic course, with potential phases of remission. On the neurophysiological level, the representation of SWS is deficient.

Secondary forms may depend on physical and environmental (e.g., pain), medical (e.g., hyperthyroidism, respiratory disorders), mental (e.g., anxiety, mood), pharmacological (e.g., caffeine, benzodiazepines, alcohol), and situational (e.g., job loss) conditions.

Over the years, several diagnostic nosologies for insomnia have been debated and

diagnostic criteria and classification have changed. The ICSD [12] and the ICSD 2nd edition [13] describe numerous primary and secondary insomnia subtypes and incorporate findings from interviews and laboratory tests. The Diagnostic and Statistical Manual of Mental Disorders IV edition (DSM-IV) [14], from 1994, also distinguishes primary and secondary insomnia. Some authors [15] highlighted that the distribution of diagnoses underlines the importance of psychiatric and behavioral factors in the assessment of insomnia and that diagnostic concordance for these diagnoses likely reflects actual clinical practice.

Some others [16] showed that the best-supported insomnia categories both from DSM-IV TR and ICSD-2 were insomnia related to another mental disorder, insomnia due to a general medical condition, breathing-related sleep disorder, circadian rhythm sleep disorder, and restless legs syndrome. The category of primary insomnia appeared to have marginal reliability and validity.

More recently, the ICSD-3 [6], as well as DSM-V [17] has made a lot of changes from the former editions [18]. All previous chronic insomnia diagnoses merge into a single *Chronic insomnia disorder* (ICSD-3) and *Insomnia Disorder* (DSM-V) diagnosis. This change in insomnia diagnostic criteria in both ICSD-3 and DSM-5 implies a paradigm shift, stresses the comorbid nature of insomnia, and calls for treatment of both insomnia and the medical disorder. That's because, first of all, overlapping primary and secondary insomnias share many symptoms and features. Second, secondary insomnia often develops an independent course over time and may remain as a clinically separate significant condition. Finally, clinical experience suggests that it is rare to encounter patients who meet the diagnostic criteria for exclusively one of the primary subtype (psychophysiological insomnia, idiopathic insomnia, inadequate sleep hygiene, and paradoxical insomnia).

Nevertheless, in the age of "precision medicine", the etiopathogenesis in a specific patient should be taken into account in the choice of both the therapeutic approach and prognosis; therefore, the distinction between primary and secondary forms cannot be based on comorbidity *per se*.

Etiopathogenesis of insomnia is complex and partially unknown. At different levels, genes, molecules, circuits, cognition, and behavior contribute to determining this disorder.

Conceptual Models of Insomnia

Insomnia is often considered to be a disorder of hyperarousal. The increased somatic, cognitive, and cortical activation could take part in the pathophysiology of insomnia along with other contributory factors [19,20].

Numerous sleep regulatory substances are linked to circadian rhythmicity and sleep regulation [21]. Endogenous molecules can be categorized as primarily wake-promoting/sleep-suppressing (e.g., catecholamines, orexins, and histamine) and sleep-promoting/wake-suppressing substances (e.g., γ -aminobutyric acid [GABA], adenosine, serotonin, melatonin, prostaglandin D2) and many of them are linked to insomnia. For example, blood serum melatonin levels are reduced [22], whilst cortisol evening and morning salivary levels are higher [23] in insomnias.

Besides, the activity of arousal and sleep centers is modulated by two critical physiologic processes: wake-dependent sleep drive (homeostatic or process S) and circadian rhythmicity (process C). Sleep propensity is regulated by the interaction of S-process and C-process. Accumulation of extracellular adenosine during prior wakefulness may be the primary input to these systems. One hypothesis based on the two-process model is that insomnia is caused by insufficient sleep propensity during the desired sleep period due to dysfunction in the S- or C-process [24,25]. Behavioral and cognitive mechanisms can also regulate sleep and contribute to, or exacerbate, insomnia [19].

A conceptual model of insomnia, the "Behavioral Model of Insomnia", by Spielman and colleagues in 1987 [26], regarding the etiology of chronic insomnia, put forward what factors should be targeted for treatment. This model suggests that insomnia is due to three main factors.

1. Predisposing factors:

- biological, including hyperarousal/hyper-reactivity and weak sleep generating system;
- psychological, including worry or the tendency to be excessively ruminative;
- social factors, such things as the bed partner, keeping an incompatible sleep schedule or social pressures.

2. Precipitating factors are acute occurrences that interact with the patient's predisposition for insomnia to produce transient sleep initiation or maintenance problems and may be:

- biological, including medical illness and injury;
 - psychological, as acute stress reactions and psychiatric illness;
 - social, such as factors that change the patient's social environment, that require a significant shift in or disrupt the subject sleep phase.
3. Perpetuating factors are maladaptive coping behavior and cognitive strategies that individuals adopt in an attempt to get more sleep [27].

TREATMENTS

Interventions aimed at preventing or treating insomnia may target various aspects of the different pathophysiologic processes [28].

Treatments can be both pharmacological and non-pharmacological. Pharmacological therapies are directly active on neurotransmission systems (GABA, 5-hydroxytryptamine—5HT aka serotonin, noradrenaline—NA, orexins, melatonin), in contrast, specific non-pharmacological techniques act on specific sleep mechanisms such as the circadian oscillator, the arousal system, and the homeostatic process through educational, cognitive, behavioral, and relaxation techniques.

Pharmacological Treatment

The pharmacological approach can rely on different pharmacological classes, interacting with varying neurotransmission systems. Currently, the most used drugs in the treatment of insomnia are benzodiazepines (BDZ) and non-benzodiazepine drugs (z drugs), to which imidazopyridines (zolpidem) and cyclopyrrolones (zopiclone) belong, all of them interacting with the GABAergic system (BDZ receptor agonists, BDZ-Ra) [29].

The choice among different BDZ molecules mainly depends on the desired duration of the hypnotic effect. As hypnotic, an ultra-short half-life (2-4 hours) medication such as triazolam, or short half-life (3-8 hours) medication such as brotizolam is usually used, while those with an intermediate or long half-life (over 10 hours) are less indicated due to the risk of residual drowsiness after awakening. An important aspect to be evaluated in the choice of the molecule is the different affinity of BDZ for the GABA

receptor complex to which they bind. The higher the receptor affinity, the more probably the drug induces tolerance and withdrawal symptoms. This phenomenon is likely due to a variation in the gene expression of the different subunits forming the GABA receptor. To reduce these effects and to avoid abuse conditions, primarily when short- or ultra-short half-life BDZs are used (usually with high receptor affinity), care should be taken not to prolong therapy far beyond four weeks, and discontinuation should also be slow (15-20 days) [30]. The most common side effects of BDZ are cognitive and attentive disorders [31,32], especially for long half-life compounds, anterograde amnesia [33], and ataxia mainly for short half-life compounds [34]. Particular caution is needed in the case of elderly patients [35], due to the slower drug elimination (risk of accumulation) or in subjects with respiratory disease due to the risk of onset or increase of sleep apnea [36]. Insomnia, anxiety, irritability, and depression are the side effects that can occur most frequently at the time of withdrawal [37]. From a neurophysiological point of view, a reduction/suppression of slow-wave sleep has been highlighted [38].

Imidazopyridines and cyclopyrrolones are ultra-short (zolpidem) and short (zopiclone) duration drugs, respectively. They can be used as BDZ substitutes, especially in occasional or transient forms of insomnia. Compared to BDZs, they have less both muscle-relaxing and anxiolytic effects and reduced influence on the sleep structure (slow-wave sleep reduction). The most common side effects after suspension are insomnia and anxiety [39]. Moreover, caution should be used in the elderly, given the possibility of confusional events and high risk of falls and fractures [40,41].

Due to tolerance, inhibition of slow-wave sleep, and risk of residual morning drowsiness from these agents, the attention of sleep specialists has recently shifted towards drugs able to enhance slow-wave sleep, to better "take care" of the neurophysiological characteristics of primary insomnia (characterized by a deficit of this type of sleep). This kind of drug is heterogeneous both in terms of the type of use (antidepressants, neuroleptics, antihistamines, antiepileptics) [42-47] and pharmacodynamics (5HT_{2a} and 5HT_{2c} receptor silent antagonists, α 2 δ Ca blockers, melatonin receptor blockers, orexin receptor antagonists). Some of these molecules (e.g., trazodone, agomelatine, mirtazapine, pre-

gabalin, quetiapine, ramelteon) have been marketed for some years and are used off label. Some others still require study or authorization in some countries (suvorexant) [48,49]. Due to the reduced blood levels of melatonin in the elderly, the administration of control release melatonin should be considered in older patients [50].

Recently, American Academy of Sleep Medicine (AASM) and European Sleep Research Society (ESRS) guidelines evaluated hypnotic drug efficacy and safety [47,48].

Unfortunately, even though some data do exist, the overall quality of evidence of recommendations is relatively low for most drugs. As a result, many commonly used drugs, including some approved by Food and Drug Administration (FDA) for the treatment of insomnia, are not recommended. Keeping in mind the weak strength of recommendation, these guidelines suggest (benefits outweigh harms) the use of GABA receptor agonists in insomnia with low/very low (eszopiclone, zaleplon, zolpidem), moderate (temazepam), and high (triazolam) quality of evidence. Some evidence (low) emerge about the use of drugs with different pharmacodynamics, as suvorexant (orexin receptor agonist), ramelteon (melatonin receptor agonist), doxepin (serotonin–norepinephrine reuptake inhibitor), but the use of other drugs (tiagabine, trazodone, melatonin) is uncertain. This evidence, reflecting a low degree of certainty in the outcome and appropriateness of care strategy, should not be considered as an indication of ineffectiveness, but suggests clinicians to use their clinical knowledge and experience and refer to the individual patients' values and preferences to determine the best course of action.

Non-Pharmacological Treatment

Although the treatment of insomnia has traditionally been pharmacological, many non-pharmacological therapies have been developed over the years. There is consensus in the scientific and professional sleep community that cognitive-behavioral therapy should be the treatment of choice for chronic insomnia [47,48,51]. The cognitive-behavioral therapy for insomnia (CBT-I) includes a complex of techniques such as relaxation techniques, stimulus control, sleep hygiene, cognitive therapy, biofeedback, chronotherapy, sleep restriction, multi-component treatment, and self-help treatments. To date, CBT-I is considered the first therapeutic

choice and ideally must be implemented before hypnotics are prescribed [47,52-57].

Different CBT-I techniques work on various factors to restore appropriate sleep hygiene, re-establish a proper sleep-wake rhythm, lower hyperarousal, and adequate homeostatic pressure. Psychological and behavioral interventions are considered to be effective in the treatment of both chronic primary insomnia (AASM-Standard) and secondary insomnia (AASM-Guideline) [58].

Sleep Hygiene

Proper sleep hygiene is an essential prerequisite for the treatment of insomnia regardless of other therapeutic approaches. Its benefit is maximized when provided as part of a comprehensive plan. The term "sleep hygiene" (SH) refers to all those behaviors that are considered as promoters of an adequate quantity and quality of sleep. Generally speaking, sleep hygiene can be conceived as a guide to "lifestyles" and behaviors that contribute to the creation of a healthy and regular sleep pattern [59,60]. Avoiding to extend the time of bed, exercising to promote good quality sleep, making sure that the sleep environment is pleasant, avoiding food that can be disruptive right before sleep, and avoiding stimulating substances (caffeine and nicotine) and alcohol in the evening are some of the rules. Therefore, the main objective of a sleep interview is to verify patients' habits and if the environment in which they sleep is following the rules of sleep hygiene. More recent adaptations, often included as part of therapeutic programs, contain more information about the role of food and the place for sleep. The American Academy of Sleep Medicine highlights insufficient evidence to recommend sleep hygiene education as a single therapy, but it should be associated with other insomnia treatments [53,56,58].

Sleep Restriction

The restriction of sleep (Sleep Restriction Therapy, SRT) has been conceived by Spielman, Saskin, and Thorpy in the '80 [61].

Most people suffering from insomnia think that spending time in bed, trying to sleep, can more easily shorten sleep latency; this incorrect behavior is considered one of the perpetuating factors of insomnia and is targeted by sleep restriction therapy.

SRT forces patients to limit the amount of time they spend in bed to an amount equal to their average total sleep time as obtained by baseline sleep diary measures. The clinical

cian establishes a fixed wake time according to the patient's needs. Once a target amount of time in bed is set, the patient's bedtime is delayed to later in the night so that the time in bed (TIB) and average total sleep time (TST) are the same. As sleep efficiency ($TST/TIB \times 100$) increases (at least 90%), patients are instructed to gradually increase the amount of time they spend in bed (15-minute). The treatment usually lasts eight weeks. The patient is also given additional advice not to take afternoon naps or to stick to prescribed bedtime.

The reduction of time spent in bed, although it may seem paradoxical for those patients who try to sleep more, necessarily influences the homeostatic and circadian regulation of sleep [62]. This method creates a mild sleep deprivation, which decreases sleep latency, reduces the wake after sleep onset, and promotes a more reliable and efficient sleep and a lower variability among nights. SRT appears to have a comparable risk profile for excessive sleepiness as CBT-I, and thus may be considered a less time-consuming alternative to CBT-I [63]. SRT is regarded as individually effective therapy (AASM-Guideline) and meets the criteria for empirically-supported psychological treatments for insomnia [56,58].

Stimulus Control

Often, it happens that people suffering from insomnia are frustrated when lying in bed trying to fall asleep, so they engage in behaviors other than sleep (e.g., reading, eating, watching TV). This behavior creates a negative association between bedtime routine and sleepiness/sleep, with the consequent inability to sleep. The Stimulus Control Therapy (SCT) [52,64] is focused on re-establishing a "positive connection" between the bed/bedroom/bedtime and a rapid-onset, well-consolidated sleep. Instructions limit the amount of time one may spend in the bedroom while awake and the kind of behaviors one may engage in while in the bed/bedroom and consequently discourages the association between bedtime and inability to sleep. Typical instructions include:

1. lie down only when sleepy;
2. avoid any behavior in the bed or bedroom other than sleep or sexual activity;
3. leave the bedroom if awake for more than 15 minutes; and
4. return to the bed only when sleepy.

This technique has the dual purpose of avoiding behaviors against sleep hygiene rules and, as in case of sleep restriction, influencing the sleep homeostat. SCT is considered an individually effective therapy (AASM-Standard) and meets the criteria for empirically-supported psychological treatments for insomnia [56,58].

Autogenic Training and Relaxation Techniques

Autogenic training is a combination of muscular relaxation and imaginative techniques. This method implies learning self-induced relaxation and imaginative techniques to reduce hyperarousal, which is frequently associated with increased sleep latency. Progressive muscle relaxation is used to diminish skeletal muscle tension [65-68]. Autogenic training involves thinking to some neutral and/or pleasant images to focus purely on their descriptive properties. Imagery training involves the patient in selecting a relaxing image or memory and evoking the image and engaging with it from a multisensory perspective. Progressive muscle relaxation is considered an individually effective therapy (AASM-Standard) and meets the criteria for empirically-supported psychological treatments for insomnia [56,58].

Cognitive Techniques

Cognitive therapy is based on the assumption that negative emotions, maladaptive behaviors, and physiological symptoms associated with specific disorders are mostly the effects of dysfunctional cognitions. As a result, a person may develop a sleep disorder caused by stressful events. Still, the disorder itself can be exacerbated by the personal concept of insomnia and its consequences, and by one's perception and interpretation of such events. Cognitive therapy is a structured psychoeducational intervention that is based on a wide variety of techniques.

It consists in guiding the patient in considering insomnia and its consequences from a more realistic and rational perspective. The most crucial point is to explain that personal interpretation of a given situation can modulate the type of emotional reaction to situation itself. Therapy begins by identifying the patient's dysfunctional thoughts about sleep. Then, it is important to encourage the patient to consider his concepts only as one of the many possible interpretations instead of absolute truth.

Different cognitive restructuring techniques (paradoxical intention, "distraction

and imagery”, revaluation, realignment, attention deviation, and hypothesis examination) can be used to change maladaptive cognitions [51,69]. The AASM stated insufficient evidence to recommend cognitive therapy as single therapy. Positive outcomes have been highlighted if part of a multifaceted intervention, even if the specific contribution of cognitive therapy remains unclear [53,56,58].

Although the American College of Physicians (ACP) recommends that all adult patients receive cognitive behavioral therapy as the initial treatment for chronic insomnia disorder (Grade of recommendations: strong; quality of evidence: moderate) [51], CBT-I is currently underused in clinical practice.

There are still many reasons that prevent CBT from being prescribed as a first therapeutic choice. First of all, if and when professional treatment is sought, it is typically from a primary care physician, and medication is often the first and only treatment provided. Second, many individuals don't want to be misunderstood and considered to have a psychological problem. Third, both individuals and physicians are often unaware of non-pharmacological therapies. Fourth, CBT is more time-consuming than prescribing medications. Finally, there are few providers with adequate training to provide CBT for insomnia [70]. For that reason, a system of standardized CBT-I training and training center accreditation should be implemented to increase the number of sleep medicine centers offering this treatment option [71,72].

CBT is sometimes associated with medications to strengthen their power or in case you need to discontinue therapy because of either physical or psychological addiction [59]. Non-pharmacological treatments are also used for those who are reluctant to use medications, although they may benefit from an occasional pharmacological treatment. On the contrary, the pharmacological approach is introduced when the subjects would not be able to follow therapy properly or when more immediate and short-term symptomatic treatment is required [73].

Numerous meta-analyses [47,55,57,74-76] demonstrated good efficacy for CBT-I, or its components, in patients with primary insomnia on sleep-related outcome parameters, and good stability of the results at follow-up assessments. On the other side, also pharmacotherapy has been widely stud-

ied [51,77-80] and, as previously discussed, variable benefits/harms ratio has been found. Generally, drugs are able to obtain fast effects and are widely available, but have the risk to produce adverse events, such as daytime sedation, and to generate tolerance and dependence. In addition, their effect may disappear after discontinuation. Conversely, psychological/behavioral therapy showed only minimal side effects, is preferred by several patients, and produces long-lasting benefits [81].

According to ACP recommendations, physicians should share a decision-making approach, which includes a proper discussion on benefits, harms, and costs of short term use of drugs, to decide whether to add pharmacological therapy in adults with chronic insomnia disorder in whom cognitive behavioral therapy for insomnia (CBT-I) alone was unsuccessful (grade: weak; evidence: low quality) [51].

On the other side, treating insomnia with CBT-I, instead of medications, has several potential advantages, such as fewer known side effects, and an explicit focus on treating the factors that may be responsible for perpetuating chronic insomnia, aiming at producing long-lasting results.

Some patients also prefer non-medication treatments [82,83]. Long-term studies consistently favor CBT-I over both benzodiazepines and non-benzodiazepines for improving sleep efficiency [84,85].

CBT-I is at least as effective for treating insomnia when compared with sleep medications. Its effects may be more durable than medications with potentially no side effects [86]. Some techniques cannot be used if patients are also affected by epilepsy or bipolar disorders [62] and, of course, CBT requires a high level of compliance, more extensive provider contact, and has a slower therapeutic action than medications. Although significant clinical gains can be made in a relatively short number of treatment sessions, CBT has a longer latency of action than BDZ or BDZ agonists.

CONCLUSION

Both CBT techniques and medications can be used in the treatment of insomnia. They should be modulated and used according to the clinical situation, and treatment effectiveness could be influenced by patient characteristics, such as age or comorbid diagnoses. Both pharmacological and non-

pharmacological approaches should be used in everyday clinics to manage insomnia and improve patients' quality of life, combining, if possible, sleep hygiene, a simplified version of sleep restriction (sleep compression), and tailored medications [83]. Typically, short-term insomnia may benefit from brief (<10 weeks) hypnotic treatments with imidazopyridines or benzodiazepines, monitoring potential abuse and side effects, together with a non-pharmacological approach (relaxation techniques, stimulus control, sleep hygiene).

In the case of chronic insomnia, often primary insomnia associated with chronic benzodiazepine treatments or abuse, the treatment should include the progressive suspension of GABAergic drugs and the simultaneous use of non-pharmacological therapies (e.g., sleep hygiene rules combined with sleep restriction and stimulus control). Pharmacological treatment with slow-wave sleep enhancers (currently off label) could also be considered in non-responders and to avoid tolerance or in case of psychiatric comorbidity (mood depression, anxiety).

The benefit of the pharmacological therapy, in the case of primary forms, usually

takes 2-6 weeks and is significantly affected by adherence to behavioral therapies; treatment is generally maintained for prolonged periods (8-12 months). In the event of recurrence, non-pharmacological techniques may be used as early as possible, with good chances of restoring a correct sleep-wake cycle without the need for pharmacological treatments.

Only a few studies [84,87,88] included a combination of CBT-I and medication treatment. Outcomes were generally comparable to those receiving CBT-I alone. In contrast, a sequential treatment strategy that commenced with six weeks of combined therapy (CBI + drug, mainly BDZ, and non-BDZ) followed by an extended 6 months of CBT alone proved superior to the continued long-term combined therapy or CBT provided in the absence of any medication [89]. Future studies should examine additional strategies for combination treatment that capitalize on the relative advantages of medications (rapid onset on the therapeutic response) and CBT-I (long-term durability of treatment gains) also in the comorbid patient.

Key points

- *Insomnia should be considered a 24-hour sleep disorder*
- *Etiopathogenesis of insomnia should be considered in managing the treatment*
- *Short-term insomnia may benefit (in term of benefits vs. harms) from brief hypnotic treatments with different quality of evidence between imidazopyridines, cyclopyrrolones (low), and benzodiazepine (moderate-high), but weak strength of recommendation in both cases (AASM and ESRS Guidelines)*
- *Hypnotics might be associated with a non-pharmacological approach (ACP: weak grade of recommendation)*
- *Chronic insomnia should be treated with non-pharmacological therapies (while GABAergic drugs should be tapered progressively off) as follow:*
 - *sleep hygiene should be added as part of a comprehensive plan (AASM);*
 - *sleep restriction is considered individually effective therapy (AASM Guideline);*
 - *stimulus control and progressive muscle relaxation are considered individually effective therapy (AASM Standard);*
 - *cognitive therapy is not recommended as single therapy but leads to positive outcomes if part of a multifaceted intervention (AASM)*
- *Treatment with slow-wave sleep enhancers should be added to CBT techniques only if needed*
- *Pharmacological and non-pharmacological therapy should be tailored to manage insomnia and improve patients' quality of life*

Funding

This article has been published without the support of sponsors.

Conflicts of interests

The authors declare he has no competing financial interests concerning the topics of this article.

REFERENCES

1. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. *Nature* 2005; 437: 1257-63; <https://doi.org/10.1038/nature04284>
2. Pace-Schott EF, Hobson JA. The neurobiology of sleep: genetics, cellular physiology and subcortical networks. *Nature Reviews Neuroscience* 2002; 3: 591-605; <https://doi.org/10.1038/nrn895>
3. Bjorness TE, Greene RW. Adenosine and sleep. *Curr Neuropharmacol* 2009; 7: 238-45; <https://doi.org/10.2174/157015909789152182>
4. Sforza E, Jouny C, Ibanez V. Cardiac activation during arousal in humans: further evidence for hierarchy in the arousal response. *Clin Neurophysiol* 2000; 1611-9; [https://doi.org/10.1016/S1388-2457\(00\)00363-1](https://doi.org/10.1016/S1388-2457(00)00363-1)
5. Halász P, Terzano M, Parrino L, et al. The nature of arousal in sleep. *J Sleep Res* 2004; 13: 1-23; <https://doi.org/10.1111/j.1365-2869.2004.00388.x>
6. American Academy of Sleep Medicine. International Classification of Sleep Disorders-Third Edition. Darien (USA, IL): American Academy of Sleep Medicine, 2014
7. Owens JA, Dalzell V. Use of the 'BEARS' sleep screening tool in a pediatric residents' continuity clinic: a pilot study. *Sleep Med* 2005; 6: 63-9; <https://doi.org/10.1016/j.sleep.2004.07.015>
8. Andreou, G, Vlachos, F, Makanikas, K. Effects of chronic obstructive pulmonary disease and obstructive sleep apnea on cognitive functions: evidence for a common nature. *Sleep disorders* 2014; 768210; <https://doi.org/10.1155/2014/768210>
9. Kielb SA, Ancoli-Israel S, Rebok GW, et al. Cognition in obstructive sleep apnea-hypopnea syndrome (OSAS): current clinical knowledge and the impact of treatment. *Neuromolecular medicine* 2012; 14: 180-93; <https://doi.org/10.1007/s12017-012-8182-1>
10. Harvey AG. Insomnia: symptom or diagnosis? *Clin Psychol Rev* 2001; 21: 1037-59; [https://doi.org/10.1016/S0272-7358\(00\)00083-0](https://doi.org/10.1016/S0272-7358(00)00083-0)
11. Primary insomnia. In: Medline Plus Medical Encyclopedia. Bethesda (USA, MD): National Library of Medicine/National Institutes of Health, 2004; <http://www.nlm.nih.gov/medlineplus/ency/article/000805.htm> (last accessed July 2020)
12. American Sleep Disorders Association. International Classification of Sleep Disorders. Rochester, MN: American Sleep Disorders Association, 1990
13. American Academy of Sleep Medicine. International Classification of Sleep Disorders. 2nd ed. Darien (USA, IL): American Academy of Sleep Medicine, 2005
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington (USA, DC): American Psychiatric Press Inc, 1994; <https://doi.org/10.1001/jama.1994.0352010009604>
15. Buysse DJ, Reynolds CF 3rd, Hauri PJ, et al. Diagnostic concordance for DSM-IV sleep disorders: a report from the APA/NIMH DSM-IV field trial. *Am J Psychiatry* 1994; 151: 1351-60; <https://doi.org/10.1176/ajp.151.9.1351>
16. Edinger JD, Wyatt JK, Stepanski EJ, et al. Testing the reliability and validity of DSM-IV-TR and ICSD-2 insomnia diagnoses. Results of a multitrait-multimethod analysis. *Arch Gen Psychiatry* 2011; 68: 992-1002; <https://doi.org/10.1001/archgenpsychiatry.2011.64>
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Washington (USA, DC): Amer Psychiatric Pub Inc., 2013
18. Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. *Chest* 2014; 146: 1387-94; <https://doi.org/10.1378/chest.14-0970>
19. Riemann D, Spiegelhalter K, Feige B, et al. The hyperarousal model of insomnia: a review of the concept and its evidence. *Sleep Med Rev* 2010; 14: 19-31; <https://doi.org/10.1016/j.smrv.2009.07.003>
20. Perlis ML, Giles DE, Mendelson WB, et al. Psychophysiological insomnia: the behavioural model and a neurocognitive perspective. *J Sleep Res* 1997; 6: 179-88; <https://doi.org/10.1046/j.1365-2869.1997.00045.x>
21. Clinton JM, Davis CJ, Zielinski MR, et al. Biochemical regulation of sleep and sleep biomarkers. *J Clin Sleep Med* 2011; 7 (5Suppl): S38-S42; <https://doi.org/10.5664/JCSM.1360>
22. Riemann D, Klein T, Rodenbeck A, et al. Nocturnal cortisol and melatonin secretion in primary insomnia. *Psychiatry Res* 2002; 113: 17-27; [https://doi.org/10.1016/S0165-1781\(02\)00249-4](https://doi.org/10.1016/S0165-1781(02)00249-4)
23. Seelig E, Keller U, Klarhöfer M, et al. Neuroendocrine regulation and metabolism of glucose and lipids in primary chronic insomnia: a prospective case-control study. *PLoS one* 2013; 8: e61780; <https://doi.org/10.1371/journal.pone.0061780>

24. Landolt HP. Sleep homeostasis: a role for adenosine in humans? *Biochem Pharmacol* 2008; 75: 2070-9; <https://doi.org/10.1016/j.bcp.2008.02.024>
25. Pace-Schott EF, Hobson JA. The neurobiology of sleep: genetics, cellular physiology and subcortical networks. *Nat Rev Neurosci* 2002; 3: 591-605; <https://doi.org/10.1038/nrn895>
26. Spielman A, Caruso L, Glovinsky P. A behavioral perspective on insomnia treatment. *Psychiatr Clin North Am* 1987; 10: 541-553
27. Perlis ML, Jungquist C, Smith MT, et al. The conceptual framework for CBT-I. In: *Cognitive Behavioral Treatment of Insomnia. A Session-by-Session Guide*. New York (USA, NY): Springer-Verlag, 2005
28. Levenson JC, Kay DB, Buysse DJ. The pathophysiology of insomnia. *Chest* 2015; 147: 1179-92; <https://doi.org/10.1378/chest.14-1617>
29. Hausken AM, Furu K, Skurtveit S, et al. Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors. *Eur J Clin Pharmacol* 2009; 65: 295-301; <https://doi.org/10.1007/s00228-008-0565-8>
30. Soyka M. Treatment of Benzodiazepine Dependence. *N Engl J Med* 2017; 376: 1147-57; <https://doi.org/10.1056/NEJMra1611832>
31. Kelly TH, Foltin RW, Serpick E, et al. Behavioral effects of alprazolam in humans. *Behav Pharmacol* 1997; 8: 47-57
32. Kozená L, Frantik E, Horváth M. Vigilance impairment after a single dose of benzodiazepines. *Psychopharmacology* 1995; 119: 39-45; <https://doi.org/10.1007/bf02246052>
33. Beracochea D. Anterograde and retrograde effects of benzodiazepines on memory. *ScientificWorldJournal* 2006; 1460-5; <https://doi.org/10.1100/tsw.2006.243>
34. WHO Review Group. Use and abuse of benzodiazepines. *Bull World Health Organ* 1983; 61: 551-62
35. Pierfite C, Macouillard G, Thicoïpe M, et al. Benzodiazepines and hip fractures in elderly people: case-control study. *BMJ* 2001; 322: 704-8; <https://doi.org/10.1136/bmj.322.7288.704>
36. Pagel JF, Parnes BL. Medications for the Treatment of Sleep Disorders: An Overview. *Prim Care Companion J Clin Psychiatry* 2001; 3: 118-25; <https://doi.org/10.4088/pcc.v03n0303>
37. Belleville, G, Morin, CM. Hypnotic discontinuation in chronic insomnia: impact of psychological distress, readiness to change, and self-efficacy. *Health* 2008; 27: 239-48; <https://doi.org/10.1037/0278-6133.27.2.239>
38. Mazza M, Losurdo A, Testani E, et al. Polysomnographic findings in a cohort of chronic insomnia patients with benzodiazepine abuse. *J Clin Sleep Med* 2014; 10: 35-42; <https://doi.org/10.5664/jcsm.3354>
39. Victorri-Vigneau C, Dailly E, Veyrac G, et al. Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. *Br J Clin Pharmacol* 2007; 64: 198-209; <https://doi.org/10.1111/j.1365-2125.2007.02861.x>
40. Wang PS, Bohn RL, Glynn RJ, et al. Zolpidem use and hip fractures in older people. *J Am Geriatr Soc* 2001; 49: 1685-90; <https://doi.org/10.1111/j.1532-5415.2001.49280.x>
41. Westerlind B, Östgren CJ, Mölsted S, et al. Use of non-benzodiazepine hypnotics is associated with falls in nursing home residents: a longitudinal cohort study. *Aging Clin Exp Res* 2019; 31: 1087-95; <https://doi.org/10.1007/s40520-018-1056-0>
42. Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. *Hum Psychopharmacol* 2005; 20: 533-59; <https://doi.org/10.1002/hup.726>
43. Wichniak A, Wierzbicka A, Wałęcka M, et al. Effects of Antidepressants on Sleep. *Curr Psychiatry Rep* 2017; 19: 63; <https://doi.org/10.1007/s11920-017-0816-4>
44. Monti JM, Torterolo P, Pandi Perumal SR. The effects of second generation antipsychotic drugs on sleep variables in healthy subjects and patients with schizophrenia. *Sleep Med Rev* 2017; 33: 51-7; <https://doi.org/10.1016/j.smrv.2016.05.002>
45. Jain SV, Glauser TA. Effects of epilepsy treatments on sleep architecture and daytime sleepiness: an evidence-based review of objective sleep metrics. *Epilepsia* 2014; 55: 26-37; <https://doi.org/10.1111/epi.12478>
46. Ozdemir PG, Karadag AS, Selvi Y, et al. Assessment of the effects of antihistamine drugs on mood, sleep quality, sleepiness, and dream anxiety. *Int J Psychiatry Clin Pract* 2014; 18: 161-8; <https://doi.org/10.3109/13651501.2014.907919>
47. Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. *J Sleep Res* 2017; 26: 675-700; <https://doi.org/10.1111/jsr.12594>

48. Sateia MJ, Buysse DJ, Krystal AD, et al. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. *J Clin Sleep Med* 2017; 13: 307-49; <https://doi.org/10.5664/jcsm.6470>
49. Kuriyama A, Tabata H. Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis. *Sleep Med Rev* 2017; 35: 1-7; <https://doi.org/10.1016/j.smr.2016.09.004>
50. Scholten RM, van Munster BC, van Kempen MF, et al. Physiological melatonin levels in healthy older people: A systematic review. *J Psychosom Res* 2016; 86: 20-7; <https://doi.org/10.1016/j.jpsychores.2016.05.005>
51. Qaseem, A, Kansagara D, Forcica MA, et al. Management of chronic insomnia disorder in adults: A clinical practice guideline from the American College of Physicians. *Ann Intern Med* 2016; 165: 125-33; <https://doi.org/10.7326/M15-2175>
52. Chesson AL Jr, Anderson WM, Littner M, et al. Practice parameters for the nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine report. Standards of Practice Committee of the American Academy of Sleep Medicine. *Sleep* 1999; 22: 1128-33; <https://doi.org/10.1093/sleep/22.8.1128>
53. Morin CM, Hauri PJ, Espie CA, et al. Nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine review. *Sleep* 1999; 22: 1134-56; <https://doi.org/10.1093/sleep/22.8.1134>
54. Petit L, Azad N, Byszewski A, et al. Non-pharmacological management of primary and secondary insomnia among older people: review of assessment tools and treatments. *Age Ageing* 2003; 32: 19-25; <https://doi.org/10.1093/ageing/32.1.19>
55. Morin CM, Culbert JP, Schwartz SM. Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. *Am J Psychiatry* 1994; 151: 1172-80; <https://doi.org/10.1176/ajp.151.8.1172>
56. Morin CM, Bootzin RR, Buysse DJ, et al. Psychological and behavioral treatment of insomnia: update of the recent evidence (1998-2004). *Sleep* 2006; 29: 1398-414; <https://doi.org/10.1093/sleep/29.11.1398>
57. Trauer JM, Qian MY, Doyle JS, et al. Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis. *Ann Intern Med* 2015; 163: 191-204; <https://doi.org/10.7326/M14-2841>
58. Morgenthaler T, Kramer M, Alessi C, et al. Practice parameters for the psychological and behavioral treatment of insomnia: an update. An American academy of sleep medicine report. *Sleep* 2006; 29: 1415-9
59. Morin CM. Cognitive-behavioral approaches to the treatment of insomnia. *J Clin Psychiatry* 2004; 65 Suppl 16: 33-40
60. Chung KF, Lee CT, Yeung WF, et al. Sleep hygiene education as a treatment of insomnia: a systematic review and meta-analysis. *Fam Pract* 2018; 35: 365-75; <https://doi.org/10.1093/fampra/cmz122>
61. Spielman AJ, Saskin P, Thorpy MJ. Treatment of chronic insomnia by restriction of time in bed. *Sleep* 1987; 10: 45-56
62. Perlis ML, Jungquist C, Smith MT, et al. Components of therapy. In: Cognitive Behavioral Treatment of Insomnia. A Session-by-Session Guide. New York (USA, NY): Springer-Verlag, 2005
63. Cheng P, Kalmbach D, Fellman-Couture C, et al. Risk of excessive sleepiness in sleep restriction therapy and cognitive behavioral therapy for insomnia: a randomized controlled trial. *J Clin Sleep Med* 2020; 16: 193-8; <https://doi.org/10.5664/jcsm.8164>
64. Bootzin RR. Stimulus control treatment for insomnia. *Proc Ann Psychol Assoc* 1972; 7: 395-6
65. Lichstein KL, Riedel BW, Wilson NM, et al. Relaxation and sleep compression for late-life insomnia: a placebo-controlled trial. *J Consult Clin Psychol* 2001; 69: 227-39; <https://doi.org/10.1037//0022-006x.69.2.227>
66. Borkovec TD, Fowles DC. Controlled investigation of the effects of progressive and hypnotic relaxation on insomnia. *J Abnorm Psychol* 1973; 82: 153-8; <https://doi.org/10.1037/h0034970>
67. Lichstein KL. Clinical relaxation strategies. New York (USA, NY): Wiley, 1988
68. Schultz JH, Luthe W. Autogenic Training. Autogenic Methods, vol I. New York (USA, NY): Grune & Stratton, 1969
69. Morin CM. Insomnia: Psychological assessment and management. New York (USA, NY): Guilford Press, 1993
70. Morin CM. Issues and challenges in implementing clinical practice guideline for the management of chronic insomnia. *J Sleep Res* 2017; 26: 673-4; <https://doi.org/10.1111/jsr.12639>

71. Baglioni C, Altena E, Bjorvatn B, et al. The European Academy for Cognitive Behavioural Therapy for Insomnia: An initiative of the European Insomnia Network to promote implementation and dissemination of treatment. *J Sleep Res* 2020; 29: e12967; <https://doi.org/10.1111/jsr.12967>
72. Baglioni C, Altena E, Bjorvatn B, et al. The European Academy for Cognitive Behavioural Therapy for Insomnia: An initiative of the European Insomnia Network to promote implementation and dissemination of treatment. *J Sleep Res* 2020; 29: e12967; <https://doi.org/10.1111/jsr.12967>
73. Hassinger AB, Bletnisky N, Dudekula R, et al. Selecting a pharmacotherapy regimen for patients with chronic insomnia [published online ahead of print, 2020 Mar 23]. *Expert Opin Pharmacother* 2020; 1-9; <https://doi.org/10.1080/14656566.2020.1743265>
74. Irwin MR, Cole JC, Nicassio PM. Comparative meta-analysis of behavioral interventions for insomnia and their efficacy in middle-aged adults and in older adults 55+ years of age. *Health Psychol* 2006; 25: 3-14; <https://doi.org/10.1037/0278-6133.25.1.3>
75. Montgomery P, Dennis J. A systematic review of non-pharmacological therapies for sleep problems in later life. *Sleep Med Rev* 2004; 8: 47-62; [https://doi.org/10.1016/S1087-0792\(03\)00026-1](https://doi.org/10.1016/S1087-0792(03)00026-1)
76. Murtagh DR, Greenwood KM. Identifying effective psychological treatments for insomnia: a meta-analysis. *J Consult Clin Psychol* 1995; 63: 79-89; <https://doi.org/10.1037//0022-006x.63.1.79>
77. Wilt TJ, MacDonald R, Brasure M, et al. Pharmacologic Treatment of Insomnia Disorder: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians. *Ann Intern Med* 2016; 165: 103-12; <https://doi.org/10.7326/M15-1781>
78. Abad VC, Guilleminault C. Insomnia in Elderly Patients: Recommendations for Pharmacological Management. *Drugs Aging* 2018; 35: 791-817; <https://doi.org/10.1007/s40266-018-0569-8>
79. Smith E, Narang P, Enja M, et al. Pharmacotherapy for Insomnia in Primary Care. *Prim Care Companion CNS Disord* 2016; 18: 10.4088/PCC.16br01930; <https://doi.org/10.4088/PCC.16br01930>
80. Kay-Stacey M, Attarian H. Advances in the management of chronic insomnia. *BMJ (Clinical research ed.)* 2016; 354: i2123; <https://doi.org/10.1136/bmj.i2123>
81. Morin CM. Combined therapeutics for insomnia: Should our first approach be behavioral or pharmacological? *Sleep Med* 2006; 7 (Suppl 1): S15-S19; <https://doi.org/10.1016/j.sleep.2006.03.005>
82. Vincent N, Lionberg C. Treatment preference and patient satisfaction in chronic insomnia. *Sleep* 2001; 24: 411-7; <https://doi.org/10.1093/sleep/24.4.411>
83. Schutte-Rodin S, Broch L, Buysse D, et al, M. Clinical guideline for the evaluation and management of chronic insomnia in adults. *J Clin Sleep Med* 2008; 4: 487-504
84. Sivertsen B, Omvik S, Pallesen S, et al. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. *JAMA* 2006; 295: 2851-8; <https://doi.org/10.1001/jama.295.24.2851>
85. McClusky HY, Milby JB, Switzer PK, et al. Efficacy of behavioral versus triazolam treatment in persistent sleep-onset insomnia. *Am J Psychiatry* 1991; 148: 121-6; <https://doi.org/10.1176/ajp.148.1.121>
86. Mitchell MD, Gehrman P, Perlis M, et al. Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review. *BMC family practice* 2012; 13: 40; <https://doi.org/10.1186/1471-2296-13-40>
87. Morin CM, Colecchi C, Stone J, et al. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. *JAMA* 1999; 281: 991-9; <https://doi.org/10.1001/jama.281.11.991>
88. Wu R, Bao J, Zhang C, et al. Comparison of sleep condition and sleep-related psychological activity after cognitive-behavior and pharmacological therapy for chronic insomnia. *Psychother Psychosom* 2006; 75: 220-8; <https://doi.org/10.1159/000092892>
89. Morin CM, Vallières A, Guay B, et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. *JAMA* 2009; 301: 2005-15; <https://doi.org/10.1001/jama.2009.682>